Before trial, both Sandoz and Zydus acknowledged that their generic versions of Otezla infringe ... reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent ...

Amgen also purchased oral immunology drug Otezla, which fits well with the ... have generated promising data and could begin to support growth within the next few years. Amgen's pipeline had ...

amgen presents new research on otezla® (apremilast) at aad 2024 date 3/9/2024 12:30:47 pm ...

Amgen has announced the availability of Otezla (apremilast) in the US for paediatric patients with moderate to severe plaque psoriasis, [a skin lesion condition]. It is the first and only pill for ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen (NASDAQ:AMGN) violated U.S. antitrust laws by forcing pharmacy benefit managers ...

Amgen continues to see “strong growth potential for Otezla” despite rival launches restricting Otezla to a 1% uptick in sales in the second quarter. The Spherix data offer support for Amgen ...

Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the SARS-CoV-2 coronavirus. Otezla ...

offering to sell or importing each of their generic versions of Otezla until February 2028. Three of Amgen's patents were the subject of the appeal. The appellate court upheld the validity of U.S ...

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in ...